Progenics Submits RELISTOR(R) Supplemental NDA for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-Cancer Pain

Progenics Pharmaceuticals, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval for the use of RELISTOR(R) (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain.RELISTOR is the first approved medication that specifically targets the underlying cause of OIC. It is currently approved and sold in the United States, European Union, Canada, Australia and other countries for the treatment of OIC in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient."This regulatory submission is an important milestone for Progenics as we work with our development and commercialization partner, Salix Pharmaceuticals, to make RELISTOR available to a broader population of patients," said Mark R. Baker, chief executive officer of Progenics.